GPRC5D-Targeted Bispecifics in Relapsed/Refractory Multiple Myeloma: Practical Expert Consensus on a New Target with Unique Adverse Events
Host: Jeffrey V. Matous, MD
\n\n Guest: Donna Catamero, NP
\n\n Guest: Ajai Chari, MD
\n\n\n \n
GPRC5D-directed therapy is associated with impressive overall response rates and substantially positive clinical outcomes in heavily pretreated relapsed/refractory multiple myeloma. Identification and appropriate management of treatment-emergent adverse events is important to ensure that patients can stay on therapy safely to achieve optimal outcomes. In this educational podcast, myeloma experts weigh in on best-practice management strategies for these toxicities.